Dr. Brentjens is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Elm and Carlton Streets
Buffalo, NY 14263Phone+1 716-845-1300
Summary
- Dr. Renier Brentjens is an oncologist in Buffalo, NY and is affiliated with Roswell Park Comprehensive Cancer Center.
Dr. Brentjens obtained an MD/PhD (microbiology) from SUNY Buffalo, completed a residency in medicine at Yale New Haven Hospital, and a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC). As a medical oncology fellow during his training at MSKCC, Dr. Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T-cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T-cell receptors termed chimeric antigen receptors (CARs). Following completion of his medical oncology training, Dr. Brentjens became the principal investigator of his own laboratory. As a PI, Dr. Brentjens successfully translated these studies to the clinical setting treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL). Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T-cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of “armored CAR T-cells” currently being translated to the clinical setting as second-generation CAR modified T-cell clinical trials. Additionally, work in the Brentjens’ lab has expanded this CAR technology to target additional tumor antigens expressed on other malignancies including solid tumors.
Dr. Brentjens also speaks multiple languages, including Dutch.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1998 - 2002
Yale-New Haven Medical CenterResidency, Internal Medicine, 1996 - 1998
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1996
Certifications & Licensure
NY State Medical License 1998 - 2025
Awards, Honors, & Recognition
- New York Magazine: Top Doctors Castle Connolly, 2014
- America's Top Doctors Castle Connolly, 2014
- Top Doctors: New York Metro Area Castle Connolly, 2014
Clinical Trials
- Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 Start of enrollment: 2007 Mar 21
- Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2005 May 01
- Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer Start of enrollment: 2005 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 745 citationsEngineering strategies to overcome the current roadblocks in CAR T cell therapySarwish Rafiq, Christopher S. Hackett, Renier J. Brentjens
Nature Reviews. Clinical Oncology. 2020-03-01 - 602 citationsToxicity and management in CAR T-cell therapy.Challice L. Bonifant, Hollie J. Jackson, Renier J. Brentjens, Kevin J. Curran
Molecular Therapy Oncolytics. 2016-01-01 - 178 citationsHematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies.Tania Jain, Andrea Knezevic, Martina Pennisi, Yunxin Chen, Josel D. Ruiz
Blood Advances. 2020-08-11
Abstracts/Posters
- Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)Renier J. Brentjens, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T CellsRenier J. Brentjens, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Clinical Factors Associated with Improved Survival Following Allogeneic HSCT after CD19 CAR Therapy in Adult Patients with Relapsed B-ALLRenier J. Brentjens, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL “Armored” CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Tr...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Expert Discussion and Guidance on New Advances, Clinical Opportunities, and Current Challenges in Treating Adults with Ph-Negative Acute Lymphoblastic Leukemia60th American Society of Hematology Annual Meeting - 11/30/2018
Press Mentions
Roswell Park Receives $1 Million Gift from the 11 Day Power PlaySeptember 24th, 2024- Treatment Options for Chronic Lymphocytic Leukemia Beyond ChemotherapyAugust 26th, 2024
- Pioneering Hematology/Oncology Expert Joins Roswell Park in Vice Chair RoleMarch 20th, 2023
- Join now to see all
Grant Support
- Adoptive Immunotherapy Of Cancer With IL-12 Secreting Tumor-Targeted T CellsNational Cancer Institute2009–2012
- Genetic Targeting Of T Cells To B Cell MalignanciesNational Cancer Institute2003–2005
Professional Memberships
- Member
Other Languages
- Dutch
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
